Is AOD-9604 Legal in Texas?

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide derived from the C-terminal fragment (amino acids 177 to 191) of human growth hormone. Researchers at Monash University developed it to retain the fat-metabolizing properties of hGH without triggering IGF-1-mediated growth effects. The peptide works primarily by stimulating lipolysis and inhibiting lipogenesis through mechanisms that appear independent of the GH receptor [1].

The METAOD Clinical Trial Program

Between 2001 and 2007, Metabolic Pharmaceuticals Pty Ltd ran a series of Phase II randomized controlled trials under the METAOD label. METAOD001 through METAOD006 collectively enrolled several hundred obese adults across Australia and the United States. The highest dose arm (1 mg/day oral) produced a statistically significant reduction in body weight compared to placebo over 12 weeks, though the effect size was modest [2].

The compound received FDA Generally Recognized as Safe (GRAS) designation for use in food in 2014 (GRAS Notice No. GRN 000551). That designation covers food-additive safety specifically. It does not constitute drug approval, does not authorize compounding, and does not establish clinical efficacy for any medical indication [3].

Why No Drug Approval Was Pursued

After Phase II results, Metabolic Pharmaceuticals did not file a New Drug Application (NDA) with the FDA. Phase III trials were never initiated. Without an approved NDA or Biologics License Application (BLA), AOD-9604 has no legal pathway to be dispensed as a finished pharmaceutical product in the United States [4].

Federal Legal Framework That Controls Access in Texas

Texas does not have a state-specific law that bans or explicitly permits AOD-9604. What governs the peptide in Texas is entirely federal law, interpreted and enforced at the state pharmacy and medical board level.

The Drug Quality and Security Act (DQSA) and 503A/503B Compounding

Congress passed the Drug Quality and Security Act in 2013, adding Sections 503A and 503B to the Federal Food, Drug, and Cosmetic Act. These sections define when compounding pharmacies can lawfully prepare drugs that are not FDA-approved [5].

503A pharmacies (traditional compounding pharmacies) may prepare compounds from bulk drug substances, but only if those substances appear on an FDA-approved positive list, or if they meet other narrow criteria. The FDA maintains a Bulks List for 503A pharmacies.

503B outsourcing facilities operate under stricter current Good Manufacturing Practice (cGMP) standards and may compound drugs that appear on a separate FDA-published list of bulk substances.

The 2023 Removal from the 503A Bulks List

This is the single most legally significant development for patients and providers. In October 2023, the FDA finalized its decision to place AOD-9604 on the list of bulk drug substances that may not be used in 503A compounding. The agency evaluated AOD-9604 under its Category 2 review and concluded that the available evidence did not support a finding that compounding it is clinically appropriate [6].

The FDA's published evaluation noted that AOD-9604 "has not been shown to be safe and effective," and that the GRAS food designation "does not establish that the substance is appropriate for compounding." Pharmacies operating under 503A rules could not legally compound AOD-9604 after that determination took effect.

AOD-9604 has not been placed on the 503B bulk substances list either, meaning 503B outsourcing facilities also lack a clear federal authorization to compound it at scale.

What "Gray Zone" Means Here

The phrase "gray zone" is used specifically because the FDA's negative 503A determination does not automatically make every preparation of AOD-9604 a federal crime for individual patients. What it does is:

1. Prohibit 503A pharmacies from preparing it under normal compounding exemptions.
2. Create significant liability exposure for any 503B facility compounding it without explicit FDA authorization.
3. Leave physician prescribing in an ambiguous position where off-label authority may conflict with compounding supply-chain legality.

A physician in Texas cannot prescribe a drug that a licensed pharmacy cannot legally compound. That chain of supply is where the practical restriction lies [7].

Texas State Pharmacy and Medical Board Rules

Texas State Board of Pharmacy (TSBP) Position

The Texas State Board of Pharmacy (TSBP) follows federal compounding law as the floor for what Texas-licensed pharmacies may do. Texas Administrative Code Title 22, Part 15 (Pharmacy Rules) does not carve out exceptions that would allow a Texas 503A pharmacy to compound substances the FDA has placed on its "do not compound" list [8].

TSBP has not issued a separate advisory specifically naming AOD-9604 as of the date of this review. The operative rule is that federal determinations under the DQSA bind Texas-licensed pharmacies. A Texas pharmacist who compounds AOD-9604 under a 503A operation after the 2023 FDA decision risks both federal enforcement action and potential TSBP disciplinary proceedings.

Texas Medical Practice Act and Physician Authority

Texas physicians operate under the Texas Medical Practice Act, which grants broad authority to prescribe approved and unapproved substances in the context of a valid patient-physician relationship. Off-label prescribing itself is legal and routine. The constraint is not the physician's prescribing authority but rather the pharmacy's ability to fill the prescription [9].

The Texas Medical Board has not published a position statement specifically banning AOD-9604 prescription. A physician who writes a prescription knowing no legally operating pharmacy can fill it would face questions about medical necessity and standard of care documentation, however.

The Patient-Physician Relationship Requirement

Texas law requires a valid patient-physician relationship before any prescription is issued. Telehealth prescriptions are permitted under Texas Occupations Code Chapter 111, amended after the pandemic to allow prescribing via synchronous audio-video visits in most cases. A peptide prescribed after a telehealth consultation with no prior in-person contact may still satisfy this requirement provided the visit meets the statutory standard of care [10].

How to Get AOD-9604 in Texas: Practical Pathways

Access is narrower than it was before October 2023 but not entirely closed for every pathway.

Pathway 1: Licensed 503B Outsourcing Facility

Some 503B facilities have continued compounding AOD-9604 by arguing they fall outside the 503A negative list's direct scope. This is legally contested. The FDA has issued warning letters to 503B facilities compounding peptides it considers to lack clinical rationale. Patients using this pathway accept the risk that the supply chain may be disrupted by FDA enforcement at any time [6].

Pathway 2: Research and Investigational Use

A physician or institution may access AOD-9604 as a research compound under an Investigational New Drug (IND) application. Individual patient INDs exist but are rarely pursued for weight-management peptides. ClinicalTrials.gov currently lists no active recruiting studies using AOD-9604 in the United States as of mid-2025 [11].

Pathway 3: Telehealth Clinics Sourcing from International Compounders

Some telehealth platforms prescribe AOD-9604 and direct patients to compounding pharmacies outside the United States. Importing prescription drugs for personal use is technically illegal under federal law, though the FDA has a longstanding informal personal-use importation policy. Relying on that policy for a peptide the FDA has specifically reviewed and declined to approve for compounding carries meaningful regulatory and quality risk [12].

What to Avoid

Purchasing AOD-9604 from research chemical websites, peptide vendors, or online marketplaces without a prescription is a federal law violation. The FDA does not recognize "research use only" labeling as a legal shield when a product is sold for human administration. Products from these sources carry no quality assurance. Independent laboratory analyses of peptide products purchased online have found dosing inaccuracies exceeding 30% in some batches.

Clinical Context: Is AOD-9604 Effective Enough to Justify the Access Complexity?

This section is not an endorsement of AOD-9604. It is background a prescribing physician needs to weigh.

What the Phase II Data Show

The METAOD trials showed that AOD-9604 at 1 mg/day oral administration produced approximately 2.1 kg greater weight loss than placebo over 12 weeks in adults with a BMI between 27 and 40 kg/m² [2]. That effect size is modest compared to approved GLP-1 receptor agonists. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [13].

The peptide has not been studied head-to-head against semaglutide, tirzepatide, or any approved anti-obesity medication.

Safety Profile From Trials

The METAOD program did not identify serious adverse events attributable to AOD-9604 at doses up to 1 mg/day oral. IGF-1 levels were not significantly elevated, supporting the original hypothesis that the peptide lacks the mitogenic risks associated with exogenous hGH [2]. Long-term safety data beyond 24 weeks do not exist in published peer-reviewed literature.

Endocrine Society Guidance on Unapproved Weight-Loss Therapies

The Endocrine Society's 2015 Clinical Practice Guideline on Pharmacological Management of Obesity states: "We recommend against the use of medications that have not been approved by regulatory agencies for obesity treatment." [14] That position applies directly to AOD-9604, which carries no FDA obesity-treatment approval.

Comparing AOD-9604 Access to Other Peptides in Texas

The regulatory picture for AOD-9604 is meaningfully worse than for some other compounded peptides.

| Peptide | 503A Status (2025) | FDA-Approved Analog | Texas Access | |---|---|---|---| | Semaglutide (compound) | Removed from 503A list (2024 shortage list expiration) | Yes (Ozempic, Wegovy) | Restricted | | Tirzepatide (compound) | Removed from 503A shortage list | Yes (Mounjaro, Zepbound) | Restricted | | AOD-9604 | Removed from 503A list (2023) | No | Restricted | | BPC-157 | Under FDA review; not on positive list | No | Gray zone | | Ipamorelin | Not on FDA positive list | No | Gray zone |

Texas patients seeking weight loss with clinical evidence behind them will find a more defensible legal and efficacy pathway through approved GLP-1 therapies than through AOD-9604 at this time.

Documentation Requirements If a Texas Physician Prescribes AOD-9604

A Texas physician who determines that prescribing AOD-9604 is appropriate for a specific patient should, at minimum:

• Document the patient's diagnosis, weight history, and prior treatment failures.
• Record informed consent that includes the peptide's unapproved status, limited efficacy data, and restricted compounding access.
• Verify the dispensing pharmacy's licensing status with both the TSBP license lookup tool and the FDA's 503B facility registration database.
• Note in the chart why approved alternatives were considered inadequate for this patient.
• Follow up within 90 days with objective outcome measures.

The Texas Medical Board's standard-of-care framework does not prohibit innovative prescribing, but it does require documented clinical rationale. A chart that shows AOD-9604 was prescribed without any prior trial of approved weight-management therapy would be difficult to defend in a board complaint proceeding [9].

Red Flags When Evaluating AOD-9604 Providers in Texas

Not every clinic offering AOD-9604 in Texas operates within the rules. Patients should be cautious if a provider:

• Issues a prescription after a questionnaire alone, with no synchronous audio-video visit.
• Cannot name the specific 503B facility dispensing the compound.
• Claims AOD-9604 is "FDA-approved" or "GRAS-approved for medical use."
• Offers the peptide as a vial for self-injection without discussing sterile reconstitution instructions and storage.
• Prices the compound significantly below what a licensed pharmacy's overhead would support (a signal of non-pharmacy sourcing).

The FDA's GRAS designation for AOD-9604 is specifically for food applications. Any provider citing GRAS as authorization for injectable peptide dispensing is misrepresenting the regulatory record [3].